| Literature DB >> 32512908 |
Juliana Baranova1, Dominik Büchner2, Werner Götz3, Margit Schulze2, Edda Tobiasch2.
Abstract
With increasing life expectancy, demands for dental tissue and whole-tooth regeneration are becoming more significant. Despite great progress in medicine, including regenerative therapies, the complex structure of dental tissues introduces several challenges to the field of regenerative dentistry. Interdisciplinary efforts from cellular biologists, material scientists, and clinical odontologists are being made to establish strategies and find the solutions for dental tissue regeneration and/or whole-tooth regeneration. In recent years, many significant discoveries were done regarding signaling pathways and factors shaping calcified tissue genesis, including those of tooth. Novel biocompatible scaffolds and polymer-based drug release systems are under development and may soon result in clinically applicable biomaterials with the potential to modulate signaling cascades involved in dental tissue genesis and regeneration. Approaches for whole-tooth regeneration utilizing adult stem cells, induced pluripotent stem cells, or tooth germ cells transplantation are emerging as promising alternatives to overcome existing in vitro tissue generation hurdles. In this interdisciplinary review, most recent advances in cellular signaling guiding dental tissue genesis, novel functionalized scaffolds and drug release material, various odontogenic cell sources, and methods for tooth regeneration are discussed thus providing a multi-faceted, up-to-date, and illustrative overview on the tooth regeneration matter, alongside hints for future directions in the challenging field of regenerative dentistry.Entities:
Keywords: amelogenesis; cementogenesis; dentinogenesis; dentogenesis; drug release materials; odontogenic cells; scaffolds; stem cells; whole-tooth regeneration
Mesh:
Substances:
Year: 2020 PMID: 32512908 PMCID: PMC7312198 DOI: 10.3390/ijms21114031
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Tooth structure and dental tissues with the respective stem cell populations. (A) The odontoblast niche is bordering dental pulp beneath the dentin with odontoblast processes projecting towards enamel. (B) Diverse cell populations are found in dental pulp, DPSCs, which can give rise to odontoblasts. (C) Cementocytes are residing in the lacunae of cellular cementum at the root apex with their cellular processes projecting towards the periodontal ligament.
Figure 2Major signaling cascades involved in amelogenesis, odontogenesis, and cementogenesis. (A) Signaling pathways modulating amelogenesis with TGF-β superfamily ligands (BMP2 and TGF-β1/2/3) playing the major role in matrix protein and metalloproteinases feedback-regulation and Runx2 being an important transcription factor. (B) Central signaling cascades of odontogenesis are depicted. The TGF-β superfamily ligands (BMP2/4 and TGFβs) regulate many odontogenic genes with ERK1/2 as convergence point and Klk4-Osx as important transcription factor tandem. (C) Major cementogenesis-related signaling cascades with Osx as the central transcription factor being regulated via Wnt/β-catenin in a feedback-loop. Ameloblast-derived products (LRAP and amelogenin) were shown modulate key cementogenic gene expression in vitro.
Cell Sources and signaling modulators useful for amelogenesis, dentinogenesis, and cementogenesis.
| Tissue | Plausible Cell Sources | Signaling Pathway/Node | Interfering Molecule(s) | |
|---|---|---|---|---|
| Stimulatory | Inhibitory | |||
| Enamel | Keratinocyte stem cells [ | Hh | Shh [ | cyclopamine [ |
| FGF | FGF8 [ | pan-FGF receptor inhibitor SU5402 [ | ||
| Wnt/β-catenin | 6-Bromoindirubin-3′-oxime (BIO) (GSK3βi) [ | GSK3β [ | ||
| BMP | BMP2/4 [ | Noggin (BMP4i) [ | ||
| TGFβ | TGF-β1,2,3 [ | |||
| Dentin | DPSCs [ | Hh | Shh [ | _ |
| FGF | FGF2 [ | PD173074 (FGFR1i) [ | ||
| Wnt/β-catenin | BIO, CHIR, Tideglusib (GSK3bi) [ | XAV939 (tankyrasei) [ | ||
| BMP | BMP2 [ | Noggin, LDN193189 [ | ||
| P2Rs | ATP, ARL 67156 (ATPasei) [ | Suramin [ | ||
| ERK1/2 | Leptin [ | PD98059 (ERK1/2i) [ | ||
| ERK1/2 | Amelogenin [ | U0126 (ERK1/2i) [ | ||
| Cementum | PDLSCs [ | Wnt/β-catenin | LiCl, Wnt3a [ | DKK1 [ |
| FGF | FGF2 [ | _ | ||
| BMP | BMP2/4 [ | FGF2 [ | ||
| TGFβ | rhTGFβ-1 [ | SIS3 (Smad3i) [ | ||
| ERK1/2 | Amelogenin [ | U0126 (ERK1/2i) [ | ||
a studies of epithelial invagination/development; b studies in vivo; the rest are cell culture-based reports.
Compilation of recently published studies emphasizing regenerative approaches of enamel, dentin, and cementum.
| Tissue | Scaffold Material | Study Model | Results | Ref. |
|---|---|---|---|---|
|
| 8DSS: Oligopeptide of eight repetitive sequences of aspartate-serine-serine | In vivo model using Sprague-Dawley rats with induced caries. | Increased remineralization by 8DSS due to inhibited enamel demineralization and promoted remineralization. | [ |
| Elastin-like polypeptide functionalized with glutamic acid residues | In vitro remineralization of bovine enamel specimens by pH cycling after immersion in biomaterial solution. | Formation of a dense layer of highly orientated apatite nanorods with mechanical properties close to natural enamel and high chemical stability against acidic impacts. | [ | |
| PAMAM-dendrimers with varying terminal groups: -NH2, -COOH, -OH | In vitro remineralization of bovine enamel specimens by pH cycling. | Remineralization is affected by electrostatic interactions between scaffold and enamel surface. PAMAM-NH2 shows the best results, followed by PAMAM-COOH. | [ | |
| ACP-loaded PAMAM dendrimers functionalized with SN15 peptide sequence. | In vitro enamel remineralization by cycling immersion in artificial saliva and demineralization solution. | Evaluated biomaterial achieves 90% higher remineralization compared to control. | [ | |
|
| Nanobioactive glass cements with or without Sr | In vitro evaluation of biocompatibility and differentiation of DPSCs. In vivo evaluation using an ectopic odontogenesis model and a tooth defect model in rats. | Fast release of bioactive Ca-, Sr- and Si-ions. | [ |
| The organic matrix of cellulose acetate, oxidized pullulan and gelatin loaded with boron-modified bioactive glass nanoparticles. | In vitro evaluation of biomineralization, biocompatibility, proliferation, and differentiation with hDPSCs. | Boron-modified bioactive glass nanoparticles exhibit promotive effects on the deposition of a CaP as well as on adhesion, migration, and differentiation of hDPSCs. | [ | |
| Biphasic collagen matrix: Inner section of lower stiffness loaded with VEGF covered by an outer section of higher stiffness loaded with BMP2. | In vitro evaluation using hDPSCs regarding biocompatibility, proliferation, and differentiation. | The direction of DPSCs differentiation is regulated by material stiffness and amplified by the respective growth factor. | [ | |
|
| retroMTA + tricalcium phosphate | In vivo test using dehiscence periodontal defects in dogs. | Significantly increased the new bone and cementum formation. The biodegradability of retroMTA is enhanced by adding TCP. | [ |
| Calcium phosphate loaded with BMP2 | In vivo periodontitis model using critical-sized supra-alveolar defects in dogs. | Significant increase in regeneration of mineralized tissues. Loading with BMP2 leads to a further 2–3-fold increase. | [ | |
| Bilayered material: FGF2-propyleneglycol alginate gel covered by BMP2-PLGA/CaP cement. | In vivo test using three wall periodontal defects in non-human primates. | Significantly enhanced regeneration of cementum and periodontal ligament. Newly formed PDL is highly vascularized. | [ | |
| PCL-based bilayered material: a flexible porous membrane delivers cell sheets and is covered by a fibrous and porous 3D compartment. | In vivo test using dehiscence periodontal defects in sheep to evaluate the potential of different cell types forming the cell sheets: Gingival cells (GCs), PDLCs, and hBM-MSCs. | Scaffolds containing BM-MSCs and PDLCs show superior new bone and cementum formation compared to scaffolds containing gingival cells. | [ |
Figure 3SEM images of agarose lyophilized (LYO) (a–c) and supercritically-dried (SCD) (d–f) and agarose/hydroxyapatite (33/76 w%) composite LYO (g–i) and SCD (k–m) at three different magnifications. The scale bars are 10 μm (left), 1 μm (middle), and 0.2 μm (right), respectively. Reproduced from Witzler et al., 2019 [171]. Open Access Copyright Permission (Creative Commons CC BY license).
Figure 4Release data of (a) adenosin triphosphate (ATP) and (b) suramin from agarose/hydroxyapatite (AG100HA0) (black), AG50HA50 (orange), and AG33HA67 (blue) scaffolds. Data fit: Weibull equation. Reproduced from Witzler et al., 2019 [171]. Open Access Copyright Permission (Creative Commons CC BY license).
Materials applicable for loading, encapsulation and drugs/signaling molecules release for promoting cell proliferation, and differentiation.
| Signaling Molecule | Material for Drug Loading/Encapsulation and Release | Application | Release Efficiency/Kinetics Tested in | Reference |
|---|---|---|---|---|
| Amelogenin | Self-assembled nanogels of cholesterol-bearing mannan as templates for hierarchical hybrid nanostructures | Amelogenin-releasing hydrogel for remineralization of enamel damage (artificial caries) | Cytotoxicity—in PDL fibroblasts; ex vivo enamel caries models of human molars | [ |
| Purmorphamine (Hh activator/Smo agonist) | Glutaraldehyde (GA)-crosslinked gelatin type B matrix (for small molecules and proteins release) | In vitro delivery system for Wnt, Hh agonists and growth factors (e.g., FGF2, VEGF) beneficial for endochondral ossification | Release kinetics (burst vs. sustained release) studied without using cell culture; released molecules bioactivity verified in cell culture/biological assays | [ |
| Poly(propylene glycol–co-lactide) dimethacrylate (PPLM) adhesives for incorporating purmorphamine and TCP | Cell attachment and response to photocured, degradable bone adhesives containing TCP and purmorphamine | MC3T3-E1 (mouse pre-osteoblast cell line) | [ | |
| PCL microspheres for encapsulating small molecules using a single emulsion oil-in-water method | Purmorphamine and retinoic acid-loaded microspheres for prolonged release during neural differentiation | Human iPSC aggregates differentiating into motor neurons | [ | |
| FGF | D-RADA16 peptide hydrogels coated on artificial bone composed of nanohydroxy-apatite/polyamide 66 (nHA/PA66) (for basic FGF release) | Porous growth factor-releasing structure for treating large bone defects | Female SD rat BM-MSCs; female SD rats with induced large bone defects | [ |
| Acetyl chitosan (chitin) gel (for binding and release of chitin binding peptide-FGF2 fusion protein) | Lysozyme-responsive (dose-dependent or activity-dependent) release of CBP-FGF2 | Studies without using cell culture/biological assays | [ | |
| Silk fibroin e-gel scaffolds (loaded with albumin = Fe3O4-bFGF conjugate) | Enhancing alkaline phosphatase, calcium deposition, and collagen synthesis during osteogenic differentiation | SaOS-2, osteogenic differentiation | [ | |
| BIO (Wnt/β-catenin activator) | Polymersomes (PMs) consisting of PEG-PCL block copolymer (approved for clinical use) loaded with BIO | BIO-loaded PMs for controlled activation of Wnt signaling and Runx2 during osteogenesis | Murine 3T3 Wnt reporter cells; Human BM-MSCs, osteogenic differentiation | [ |
| None | Local application of Wnt pathway modulators (BIO, CHIR, and Tegusib) to promote dentine regeneration | Wistar rats and CD1 mice molar damage | [ | |
| BMP2 | Porous silica–calcium phosphate composite (SCPC50) (loaded with rhBMP2) | Sustained release of fhBMP2 for alveolar ridge augmentation in saddle-type defect | Mongrel dog with induced mandible defect | [ |
| Calcium phosphate (Ca-P)/poly(L-lactic acid) (PLLA) nanocomposites loaded with rhBMP2 | 3D Ca-P-PLLA scaffold sustainably releasing Ca2+ and rhBMP2 for enhanced osteogenesis | Human BM-MSCs, osteogenic differentiation | [ | |
| Poly(lactic-co-glycolic acid)-multistage vector composite microspheres (PLGA-MSV) (for BMP2 release) | Controlled prolonged release of BMP2 for osteoinduction of rat BM-MSCs | Male SD rat BM-MSCs, osteogenic differentiation | [ | |
| TGF-β 1, 3 | Poly(ethylene oxide terephthalate)/ | Sustained delivery of growth factors (TGF-β1, PDGF-ββ, IGF-1) using a layer by layer assembly for supporting fibroblast attachment and proliferation | TK173 (human renal fibroblast cell line), neonatal rat dermal fibroblasts (nRDFs) | [ |
| Poly(vinylidene fluoride) (PVDF) nanofibers fabricated via electro-spinning method with/without chitosan nanoparticles (loaded with TGF-β1) | PVDF-TGF-β1 as a bio-functionalscaffold for enhancing smooth muscle cells (SMC) differentiation | AT-MSCs, SMC differentiation | [ | |
| Alginate nanogel with cross-junction microchannels (encapsulating TGF-β3) | Controlled release of TGF-β3 from polymeric nanogel for enhanced chondrogenesis | Human MSCs, chondrogenic differentiation | [ | |
| ATP, suramin (P2XR activators) | Albumin nanoparticles (aNPs) of low polydispersity loaded with ATP and coated with erythrocyte membrane (EM) | EM-aNPs developed as a delivery vehicle for ATP to be used as an anticancer agent | HeLa, HEK-293 cell lines | [ |
| Hydroxyapatite (HA)/agarose hybrids for ATP and suramin release | ATP and suramin release for hard tissue formation | Release kinetic studies without cells (see | [ |